Guardant Health, Inc. (GH)
NASDAQ: GH · Real-Time Price · USD
93.02
+0.61 (0.66%)
At close: Oct 31, 2025, 4:00 PM EDT
92.88
-0.14 (-0.15%)
After-hours: Oct 31, 2025, 7:56 PM EDT
Guardant Health Revenue
Guardant Health had revenue of $265.20M in the quarter ending September 30, 2025, with 38.50% growth. This brings the company's revenue in the last twelve months to $902.57M, up 30.38% year-over-year. In the year 2024, Guardant Health had annual revenue of $739.02M with 31.04% growth.
Revenue (ttm)
$902.57M
Revenue Growth
+30.38%
P/S Ratio
12.79
Revenue / Employee
$446,595
Employees
2,021
Market Cap
11.72B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 739.02M | 175.07M | 31.04% |
| Dec 31, 2023 | 563.95M | 114.41M | 25.45% |
| Dec 31, 2022 | 449.54M | 75.89M | 20.31% |
| Dec 31, 2021 | 373.65M | 86.92M | 30.32% |
| Dec 31, 2020 | 286.73M | 72.36M | 33.75% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.11B |
GH News
- 12 hours ago - Guardant Health Beats Expectations: Shield, Quest, And AI Catalysts - Seeking Alpha
- 1 day ago - Guardant Health: Business Continues To Gather Pace - Seeking Alpha
- 1 day ago - Guardant Health, Inc. (GH) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 2 days ago - Guardant Health Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance - Business Wire
- 4 days ago - Guardant Health and Zephyr AI Announce Partnership to Unlock Drug Response Predictions and Biomarker Insights - Business Wire
- 5 days ago - Guardant Health to Share Data Supporting Critical Role of Blood-Based Testing in Improving Cancer Screening Adherence at ACG 2025 - Business Wire
- 16 days ago - Guardant Health and Collaborators to Present New Data Across the Cancer Care Continuum at ESMO 2025 - Business Wire
- 22 days ago - Guardant Health to Report Third Quarter 2025 Financial Results on October 29, 2025 - Business Wire